Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $22.6 million.

  • Tango Therapeutics' Gains from Investment Securities rose 1391.8% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year increase of 1391.8%. This contributed to the annual value of $19.6 million for FY2024, which is 1720.99% up from last year.
  • Tango Therapeutics' Gains from Investment Securities amounted to $22.6 million in Q3 2025, which was up 1391.8% from $23.7 million recorded in Q2 2025.
  • Tango Therapeutics' Gains from Investment Securities' 5-year high stood at $23.7 million during Q2 2025, with a 5-year trough of -$83000.0 in Q4 2021.
  • For the 5-year period, Tango Therapeutics' Gains from Investment Securities averaged around $9.8 million, with its median value being $12.4 million (2022).
  • The largest annual percentage gain for Tango Therapeutics' Gains from Investment Securities in the last 5 years was 15827865.38% (2024), contrasted with its biggest fall of 80000.0% (2024).
  • Quarter analysis of 5 years shows Tango Therapeutics' Gains from Investment Securities stood at -$83000.0 in 2021, then soared by 981.93% to $732000.0 in 2022, then crashed by 100.14% to -$1000.0 in 2023, then crashed by 800.0% to -$9000.0 in 2024, then skyrocketed by 251002.83% to $22.6 million in 2025.
  • Its last three reported values are $22.6 million in Q3 2025, $23.7 million for Q2 2025, and $56000.0 during Q1 2025.